(BCI) abrdn Bloomberg All - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US0032611040
BCI: ETF, Futures, Index
The abrdn Bloomberg All Commodity Strategy K-1 Free ETF (BCI) is designed to track the performance of the Bloomberg Commodity IndexSM (BCOM), a benchmark that represents a fully collateralized investment in a diversified basket of physical commodity futures contracts. The index is structured to provide exposure to a broad range of commodities, including energy, agriculture, metals, and livestock, with weights determined by liquidity and production levels. The fund achieves its investment objective by holding exchange-traded commodity futures contracts through a wholly-owned subsidiary domiciled in the Cayman Islands, allowing it to efficiently access global commodity markets. As a non-diversified fund, it may concentrate its investments in a limited number of commodities or sectors, which can lead to higher volatility compared to diversified portfolios.
The ETF provides investors with a liquid and transparent way to gain exposure to the commodities market without directly holding physical assets or individual futures contracts. By utilizing a Cayman Islands subsidiary, the fund aims to optimize its tax efficiency and operational structure, particularly for U.S. investors. The funds holdings are periodically rolled to maintain exposure to the underlying commodities, and it is designed to minimize contango effects that can impact futures-based investments. The BCOM index is widely regarded as a leading benchmark for commodity futures investments, with a focus on liquidity, diversification, and representation of global commodity markets.
Additional Sources for BCI ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
BCI ETF Overview
Market Cap in USD | 1,443m |
Category | Commodities Broad Basket |
TER | 0.26% |
IPO / Inception | 2017-03-30 |
BCI ETF Ratings
Growth Rating | 56.0 |
Fundamental | - |
Dividend Rating | 47.6 |
Rel. Strength | 9.59 |
Analysts | - |
Fair Price Momentum | 20.16 USD |
Fair Price DCF | - |
BCI Dividends
Dividend Yield 12m | 3.22% |
Yield on Cost 5y | 5.74% |
Annual Growth 5y | 34.12% |
Payout Consistency | 61.4% |
Payout Ratio | % |
BCI Growth Ratios
Growth Correlation 3m | -55.7% |
Growth Correlation 12m | 63.1% |
Growth Correlation 5y | 60.3% |
CAGR 5y | 12.69% |
CAGR/Max DD 5y | 0.48 |
Sharpe Ratio 12m | 0.14 |
Alpha | -6.52 |
Beta | 0.385 |
Volatility | 14.92% |
Current Volume | 251.8k |
Average Volume 20d | 389.3k |
As of May 23, 2025, the stock is trading at USD 20.64 with a total of 251,808 shares traded.
Over the past week, the price has changed by +0.24%, over one month by -0.24%, over three months by -2.87% and over the past year by +0.47%.
Partly, yes. Based on ValueRay´s Analyses, abrdn Bloomberg All (NYSE ARCA:BCI) is currently (May 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 55.99 and therefor an somewhat technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BCI is around 20.16 USD . This means that BCI is currently overvalued and has a potential downside of -2.33%.
abrdn Bloomberg All has no consensus analysts rating.
According to our own proprietary Forecast Model, BCI abrdn Bloomberg All will be worth about 22.2 in May 2026. The stock is currently trading at 20.64. This means that the stock has a potential upside of +7.36%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 22.2 | 7.4% |